Form D · Venture Capital Fund
EQT Life Sciences 8-Core Cooperatief U.A.
Amsterdam, P7 · CIK 0002096488
Offering snapshot reported Apr 28, 2026 · SEC filing
- Reported sold
- Yet to sell Indefinite offering
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 28, 2026 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity, Pooled investment fund
- Exemptions
- 06b, 3C, 3C.1, 3C.7
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-582059
Source: Form D, filed Apr 28, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| N/A Eqt Life Sciences 8 Director B.V. | Promoter |
| Cillian Robert King | Executive |
| Rene Robert Kuijten | Executive |
| Philippus Scheltens | Executive |
| Felice Isabel Verduyn Van Weegen | Executive |
Issuer details
Industry: Pooled Investment Fund (See others in industry)
Address:
Johannes Vermeerplein 9
Amsterdam, P7, 1071 DV
Amsterdam, P7, 1071 DV